The LL-100 panel is a group of 100 human leukemia and lymphoma cell line,[1] can be used in model of biomedical research.[2]

Purpose

LL-100 panel cell lines cover the full spectrum of human leukemia and lymphoma including T-cell, B-cell and myeloid malignancies.[1]

List of LL-100 Cell Lines

Pre-B-ALL

Cell lineSexAgeRefCellosaurus
697Male12Y[3]CVCL_0079
KOPN-8Female3M[4]CVCL_1866
NALM-6Male19Y[5]CVCL_0092
REHFemale15Y[6]CVCL_1650
SEMFemale5Y[7]CVCL_0095

B-NHL: Burkitt/B-ALL

Cell lineSexAgeRefCellosaurus
BJABFemale5Y[8]CVCL_5711
Daudi cellMale16Y[9]CVCL_0008
RajiMale11Y[10]CVCL_0511
RAMOSMale3Y[11]CVCL_0597
VALFemale50Y[12]CVCL_1819

B-NHL: CLL/PLL

Cell lineSexAgeRefCellosaurus
HG-3Male70Y[13]CVCL_Y547
JVM-3Male73Y[14]CVCL_1320
JVM-13Male60-69Y[15]CVCL_1318
MEC-1Male61Y[16]CVCL_1870
PGA-1Maleunspecified[17]CVCL_Y545

B-NHL: DLBCL ABC

Cell lineSexAgeRefCellosaurus
NU-DHL-1Male73Y[18]CVCL_1876
OCI-Ly3Male52Y[19]CVCL_8800
Ri-1Female57Y[20]CVCL_1885
U-2932Female29Y[21]CVCL_1896
U-2946Male52Y[22]CVCL_X503

B-NHL: DLBCL GC

Cell lineSexAgeRefCellosaurus
DoHH2Male60Y[23]CVCL_1179
OCI-Ly7Male48Y[19]CVCL_1881
OCI-Ly19Female27Y[24]CVCL_1878
SU-DHL-4Male38Y[25]CVCL_0539
SU-DHL-6Male43Y[25]CVCL_2206
WSU-DLCL2Male41Y[26]CVCL_1902

B-NHL: HCL

Cell lineSexAgeRefCellosaurus
BONNA-12Male46Y[27]CVCL_1090
Hair-MMale86Y[28]CVCL_B401
HC-1Male56Y[29]CVCL_1243

B-NHL: MCL

Cell lineSexAgeRefCellosaurus
Granta-519Female58Y[30]CVCL_1818
JeKo-1Female78Y[31]CVCL_1865
JVM-2Female63Y[14]CVCL_1319
MinoMale68Y[32]CVCL_1872
REC-1Male61Y[33]CVCL_1884

B-NHL: PEL

Cell lineSexAgeRefCellosaurus
BC-3Male85Y[34]CVCL_1080
BCBL-1Male40Y[35]CVCL_0165
CRO-AP2Male49Y[36]CVCL_1147
CRO-AP5Male35Y[37]CVCL_1148

B-NHL: PMBL

Cell lineSexAgeRefCellosaurus
U-2940Female18Y[38]CVCL_1897

Multiple Myeloma/PCL

Cell lineSexAgeRefCellosaurus
KMS-12-BMFemale64Y[39]CVCL_1334
L-363Female36Y[40]CVCL_1357
LP-1Female56Y[41]CVCL_0012
OPM-2Female56Y[42]CVCL_1625
RPMI-8226Male61Y[43]CVCL_0014
U-266Male53Y[44]CVCL_0566

Hodgkin Lymphoma

Cell lineSexAgeRefCellosaurus
HDLM-2Male74Y[45]CVCL_0009
KM-H2Male37Y[46]CVCL_1330
L-428Female37Y[45]CVCL_1361
L-1236Male34Y[47]CVCL_2096
SUP-HD1Male37Y[48]CVCL_2208

T-ALL/T-LL

Cell lineSexAgeRefCellosaurus
CCRF-CEMFemale3Y11M[49]CVCL_0207
DND-41Male13Y[50]CVCL_2022
HPB-ALLMale14Y[51]CVCL_1820
JurkatMale14Y[52]CVCL_0065
MOLT-4Male19Y[53]CVCL_0013
RPMI-8402Female16Y[54]CVCL_1667

Mature T-Malignancy

Cell lineSexAgeRefCellosaurus
DERL-7Male30Y[55]CVCL_2017
HHMale61Y[56]CVCL_1280
MOTN-1Female65Y[57]CVCL_2127

NK Malignancy

Cell lineSexAgeRefCellosaurus
KHYG-1Female45Y[58]CVCL_2976
NK-92Male50Y[59]CVCL_2142
YTMale15Y[60]CVCL_1797

ALCL

Cell lineSexAgeRefCellosaurus
DELMale12Y[61]CVCL_1170
SR-786Male11Y[62]CVCL_1711
SU-DHL-1Male10Y[63]CVCL_0538
SUP-M2Female5Y[64]CVCL_2209

AML myelocytic

Cell lineSexAgeRefCellosaurus
EoL-1Male33Y[65]CVCL_0258
HL-60Female36Y[66]CVCL_0002
Kasumi-1Male7Y[67]CVCL_0589
KG-1Male59Y[68]CVCL_0374
NB4Female23Y[69]CVCL_0005
OCI-AML3Male57Y[70]CVCL_1844
SKNO-1Male22Y[71]CVCL_2196

AML monocytic

Cell lineSexAgeRefCellosaurus
ME-1Male40Y[72]CVCL_2110
MOLM-13Male20Y[73]CVCL_2119
Mono-Mac-6Male64Y[74]CVCL_1426
MUTZ-3Male29Y[75]CVCL_1433
THP-1Male1Y[76]CVCL_0006
U-937Male37Y[77]CVCL_0007

AML erythroid

Cell lineSexAgeRefCellosaurus
F-36PMale68Y[78]CVCL_2037
HELMale30Y[79]CVCL_0001
OCI-M2unspecified56Y[80]CVCL_2150
TF-1Male35Y[81]CVCL_0559

AML megakaryocytic

Cell lineSexAgeRefCellosaurus
CMKMale10M[82][83]CVCL_0216
ELF-153Male41Y[84]CVCL_2031
M-07eFemale6M[85]CVCL_2106
MEGALFemaleunspecified[86]CVCL_1833
MKPL-1Male66Y[87]CVCL_2116
UT-7Male64Y[83]CVCL_2233

CML myeloid BC

Cell lineSexAgeRefCellosaurus
EM-2Female5Y[88]CVCL_1196
K-562Female53Y[89][90]CVCL_0004
KCL-22Female32Y[91]CVCL_2091
Ku812Male38Y[92]CVCL_0379
LAMA-84Female29Y[93]CVCL_0388
MOLM-20Female63Y[86]CVCL_2121

CML lymphoid BC

Cell lineSexAgeRefCellosaurus
BV-173Male45Y[94]CVCL_0181
CML-T1Female36Y[95]CVCL_1126
NALM-1Female3Y[96]CVCL_0091
TK-6Male30Y[97]CVCL_X907

MPN

Cell lineSexAgeRefCellosaurus
SET-2Female71Y[98]CVCL_2187

See also

References

  1. 1 2 Quentmeier, H; Pommerenke, C; Dirks, WG; Eberth, S; Koeppel, M; MacLeod, RAF; Nagel, S; Steube, K; Uphoff, CC; Drexler, HG (3 June 2019). "The LL-100 panel: 100 cell lines for blood cancer studies". Scientific Reports. 9 (1): 8218. Bibcode:2019NatSR...9.8218Q. doi:10.1038/s41598-019-44491-x. PMC 6547646. PMID 31160637.
  2. ↑ Drexler, HG; Quentmeier, H (13 August 2020). "The LL-100 Cell Lines Panel: Tool for Molecular Leukemia-Lymphoma Research". International Journal of Molecular Sciences. 21 (16): 5800. doi:10.3390/ijms21165800. PMC 7461097. PMID 32823535.
  3. ↑ Findley HW, Jr; Cooper, MD; Kim, TH; Alvarado, C; Ragab, AH (December 1982). "Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes". Blood. 60 (6): 1305–9. doi:10.1182/blood.V60.6.1305.1305. PMID 6982733.
  4. ↑ Uphoff, CC; MacLeod, RA; Denkmann, SA; Golub, TR; Borkhardt, A; Janssen, JW; Drexler, HG (March 1997). "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines". Leukemia. 11 (3): 441–7. doi:10.1038/sj.leu.2400571. PMID 9067587. S2CID 37823510.
  5. ↑ Hurwitz, R; Hozier, J; LeBien, T; Minowada, J; Gajl-Peczalska, K; Kubonishi, I; Kersey, J (February 1979). "Characterization of a leukemic cell line of the pre-B phenotype". International Journal of Cancer. 23 (2): 174–80. doi:10.1002/ijc.2910230206. PMID 83966. S2CID 29853203.
  6. ↑ Rosenfeld, C; Goutner, A; Venuat, AM; Choquet, C; Pico, JL; Dore, JF; Liabeuf, A; Durandy, A; Desgrange, C; De The, G (April 1977). "An effect human leukaemic cell line: Reh". European Journal of Cancer. 13 (4–5): 377–9. doi:10.1016/0014-2964(77)90085-8. PMID 194778.
  7. ↑ Greil, J; Gramatzki, M; Burger, R; Marschalek, R; Peltner, M; Trautmann, U; Hansen-Hagge, TE; Bartram, CR; Fey, GH; Stehr, K (February 1994). "The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7". British Journal of Haematology. 86 (2): 275–83. doi:10.1111/j.1365-2141.1994.tb04726.x. PMID 8199015. S2CID 44321104.
  8. ↑ Menezes, J; Leibold, W; Klein, G; Clements, G (July 1975). "Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma". Biomédicine. 22 (4): 276–84. PMID 179629.
  9. ↑ Nadkarni, JS; Nadkarni, JJ; Clifford, P; Manolov, G; Fenyö, EM; Klein, E (January 1969). "Characteristics of new cell lines derived from Burkitt lymphomas". Cancer. 23 (1): 64–79. doi:10.1002/1097-0142(196901)23:1<64::aid-cncr2820230107>3.0.co;2-m. PMID 4178827. S2CID 46405882.
  10. ↑ PULVERTAFT, JV (1 February 1964). "Cytology of Burkitt's Tumour (African Lymphoma)". Lancet. 1 (7327): 238–40. doi:10.1016/s0140-6736(64)92345-1. PMID 14086209.
  11. ↑ Klein, G; Giovanella, B; Westman, A; Stehlin, JS; Mumford, D (1975). "An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection". Intervirology. 5 (6): 319–34. doi:10.1159/000149930. PMID 181343.
  12. ↑ Kerckaert, JP; Deweindt, C; Tilly, H; Quief, S; Lecocq, G; Bastard, C (September 1993). "LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas". Nature Genetics. 5 (1): 66–70. doi:10.1038/ng0993-66. PMID 8220427. S2CID 12575122.
  13. ↑ Rosén, A; Bergh, AC; Gogok, P; Evaldsson, C; Myhrinder, AL; Hellqvist, E; Rasul, A; Björkholm, M; Jansson, M; Mansouri, L; Liu, A; Teh, BT; Rosenquist, R; Klein, E (1 January 2012). "Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection". Oncoimmunology. 1 (1): 18–27. doi:10.4161/onci.1.1.18400. PMC 3376971. PMID 22720208.
  14. 1 2 Melo, JV; Brito-Babapulle, V; Foroni, L; Robinson, DS; Luzzatto, L; Catovsky, D (15 October 1986). "Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement". International Journal of Cancer. 38 (4): 531–8. doi:10.1002/ijc.2910380413. PMID 3093393. S2CID 10813284.
  15. ↑ Melo, JV; Foroni, L; Brito-Babapulle, V; Luzzatto, L; Catovsky, D (July 1988). "The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement". Clinical and Experimental Immunology. 73 (1): 23–8. PMC 1541467. PMID 3262465.
  16. ↑ Stacchini, A; Aragno, M; Vallario, A; Alfarano, A; Circosta, P; Gottardi, D; Faldella, A; Rege-Cambrin, G; Thunberg, U; Nilsson, K; Caligaris-Cappio, F (February 1999). "MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation". Leukemia Research. 23 (2): 127–36. doi:10.1016/s0145-2126(98)00154-4. PMID 10071128.
  17. ↑ Lewin, N; Aman, P; Mellstedt, H; Zech, L; Klein, G (15 June 1988). "Direct outgrowth of in vivo Epstein-Barr virus (EBV)-infected chronic lymphocytic leukemia (CLL) cells into permanent lines". International Journal of Cancer. 41 (6): 892–5. doi:10.1002/ijc.2910410621. PMID 2836321. S2CID 38575113.
  18. ↑ Epstein, AL; Variakojis, D; Berger, C; Hecht, BK (15 May 1985). "Use of novel chemical supplements in the establishment of three human malignant lymphoma cell lines (NU-DHL-1, NU-DUL-1, and NU-AMB-1) with chromosome 14 translocations". International Journal of Cancer. 35 (5): 619–27. doi:10.1002/ijc.2910350509. PMID 2581902. S2CID 38530935.
  19. 1 2 Tweeddale, ME; Lim, B; Jamal, N; Robinson, J; Zalcberg, J; Lockwood, G; Minden, MD; Messner, HA (May 1987). "The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor". Blood. 69 (5): 1307–14. doi:10.1182/blood.V69.5.1307.1307. PMID 3567358.
  20. ↑ Th'ng, KH; Garewal, G; Kearney, L; Rassool, F; Melo, JV; White, H; Catovsky, D; Foroni, L; Luzzatto, L; Goldman, JM (15 January 1987). "Establishment and characterization of three new malignant lymphoid cell lines". International Journal of Cancer. 39 (1): 89–93. doi:10.1002/ijc.2910390116. PMID 3098690. S2CID 23849509.
  21. ↑ Amini, RM; Berglund, M; Rosenquist, R; Von Heideman, A; Lagercrantz, S; Thunberg, U; Bergh, J; Sundström, C; Glimelius, B; Enblad, G (November 2002). "A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma". Leukemia & Lymphoma. 43 (11): 2179–89. doi:10.1080/1042819021000032917. PMID 12533045. S2CID 23476994.
  22. ↑ Fridberg, M; Servin, A; Anagnostaki, L; Linderoth, J; Berglund, M; Söderberg, O; Enblad, G; Rosén, A; Mustelin, T; Jerkeman, M; Persson, JL; Wingren, AG (November 2007). "Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN". Leukemia & Lymphoma. 48 (11): 2221–32. doi:10.1080/10428190701636443. PMID 17926183. S2CID 17523509.
  23. ↑ Kluin-Nelemans, HC; Limpens, J; Meerabux, J; Beverstock, GC; Jansen, JH; de Jong, D; Kluin, PM (March 1991). "A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21)". Leukemia. 5 (3): 221–4. PMID 1849602.
  24. ↑ Chang, H; Blondal, JA; Benchimol, S; Minden, MD; Messner, HA (September 1995). "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines". Leukemia & Lymphoma. 19 (1–2): 165–71. doi:10.3109/10428199509059672. PMID 8574164.
  25. 1 2 Epstein, AL; Herman, MM; Kim, H; Dorfman, RF; Kaplan, HS (May 1976). "Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse". Cancer. 37 (5): 2158–76. doi:10.1002/1097-0142(197605)37:5<2158::aid-cncr2820370503>3.0.co;2-f. PMID 177185. S2CID 6013844.
  26. ↑ Al-Katib, AM; Smith, MR; Kamanda, WS; Pettit, GR; Hamdan, M; Mohamed, AN; Chelladurai, B; Mohammad, RM (May 1998). "Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts". Clinical Cancer Research. 4 (5): 1305–14. PMID 9607591.
  27. ↑ Wientjens, GJ; Jansen, JH; Wessels, HW; Kibbelaar, RE; Beverstock, GC; Brederoo, P; Kluin-Nelemans, HC (1991). "Characterization of a New Human B Cell Line (Bonna-12) with Trisomy 9 and Trisomy 12 Chromosomal Abnormality". Leukemia & Lymphoma. 5 (5–6): 415–22. doi:10.3109/10428199109067637. PMID 27463354.
  28. ↑ Matsuo, Y; Sagawa, K; Yokoyama, M; Koga, T; Yamaguchi, T; Morita, M; Minowada, J (November 1983). "[Establishment and characterization of hairy cell leukemia cell line (Hair-M)]". Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society. 46 (6): 1222–32. PMID 6608852.
  29. ↑ Schiller, JH; Bittner, G; Meisner, LF; Oberley, TD; Norback, D; Schwabe, M; Faltynek, CR; Raab-Traub, N (May 1991). "Establishment and characterization of an Epstein-Barr virus spontaneously transformed lymphocytic cell line derived from a hairy cell leukemia patient". Leukemia. 5 (5): 399–407. PMID 1851909.
  30. ↑ Lukas, J; Jadayel, D; Bartkova, J; Nacheva, E; Dyer, MJ; Strauss, M; Bartek, J (August 1994). "BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation". Oncogene. 9 (8): 2159–67. PMID 8036001.
  31. ↑ Jeon, HJ; Kim, CW; Yoshino, T; Akagi, T (September 1998). "Establishment and characterization of a mantle cell lymphoma cell line". British Journal of Haematology. 102 (5): 1323–6. doi:10.1046/j.1365-2141.1998.00911.x. PMID 9753063. S2CID 29818033.
  32. ↑ Lai, R; McDonnell, TJ; O'Connor, SL; Medeiros, LJ; Oudat, R; Keating, M; Morgan, MB; Curiel, TJ; Ford, RJ (September 2002). "Establishment and characterization of a new mantle cell lymphoma cell line, Mino". Leukemia Research. 26 (9): 849–55. doi:10.1016/s0145-2126(02)00013-9. PMID 12127561.
  33. ↑ Szepetowski, P; Simon, MP; Grosgeorge, J; Huebner, K; Bastard, C; Evans, GA; Tsujimoto, Y; Birnbaum, D; Theillet, C; Gaudray, P (April 1992). "Localization of 11q13 loci with respect to regional chromosomal breakpoints". Genomics. 12 (4): 738–44. doi:10.1016/0888-7543(92)90303-a. PMID 1572647.
  34. ↑ Arvanitakis, L; Mesri, EA; Nador, RG; Said, JW; Asch, AS; Knowles, DM; Cesarman, E (1 October 1996). "Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus". Blood. 88 (7): 2648–54. doi:10.1182/blood.V88.7.2648.bloodjournal8872648. PMID 8839859.
  35. ↑ Renne, R; Zhong, W; Herndier, B; McGrath, M; Abbey, N; Kedes, D; Ganem, D (March 1996). "Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture". Nature Medicine. 2 (3): 342–6. doi:10.1038/nm0396-342. PMID 8612236. S2CID 20384290.
  36. ↑ Carbone, A; Cilia, AM; Gloghini, A; Canzonieri, V; Pastore, C; Todesco, M; Cozzi, M; Perin, T; Volpe, R; Pinto, A; Gaidano, G (14 November 1997). "Establishment of HHV-8-positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions". International Journal of Cancer. 73 (4): 562–9. doi:10.1002/(sici)1097-0215(19971114)73:4<562::aid-ijc18>3.0.co;2-b. PMID 9389573. S2CID 32367275.
  37. ↑ Carbone, A; Cilia, AM; Gloghini, A; Capello, D; Todesco, M; Quattrone, S; Volpe, R; Gaidano, G (September 1998). "Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8". British Journal of Haematology. 102 (4): 1081–9. doi:10.1046/j.1365-2141.1998.00877.x. PMID 9734661. S2CID 23440348.
  38. ↑ Sambade, C; Berglund, M; Lagercrantz, S; Sällström, J; Reis, RM; Enblad, G; Glimelius, B; Sundström, C (1 February 2006). "U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma". International Journal of Cancer. 118 (3): 555–63. doi:10.1002/ijc.21417. PMID 16106419. S2CID 12837372.
  39. ↑ Ohtsuki, T; Yawata, Y; Wada, H; Sugihara, T; Mori, M; Namba, M (October 1989). "Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)". British Journal of Haematology. 73 (2): 199–204. doi:10.1111/j.1365-2141.1989.tb00252.x. PMID 2479409. S2CID 29676750.
  40. ↑ Diehl, V; Schaadt, M; Kirchner, H; Hellriegel, KP; Gudat, F; Fonatsch, C; Laskewitz, E; Guggenheim, R (20 June 1978). "Long-term cultivation of plasma cell leukemia cells and autologous lymphoblasts (LCL) in vitro: a comparative study". Blut. 36 (6): 331–8. doi:10.1007/BF01000590. PMID 207377. S2CID 22828123.
  41. ↑ Pegoraro, L; Malavasi, F; Bellone, G; Massaia, M; Boccadoro, M; Saglio, G; Guerrasio, A; Benetton, G; Lombardi, L; Coda, R (March 1989). "The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation". Blood. 73 (4): 1020–7. doi:10.1182/blood.V73.4.1020.1020. PMID 2784066.
  42. ↑ Katagiri, S; Yonezawa, T; Kuyama, J; Kanayama, Y; Nishida, K; Abe, T; Tamaki, T; Ohnishi, M; Tarui, S (15 August 1985). "Two distinct human myeloma cell lines originating from one patient with myeloma". International Journal of Cancer. 36 (2): 241–6. doi:10.1002/ijc.2910360217. PMID 3926660. S2CID 20506312.
  43. ↑ Matsuoka, Y; Moore, GE; Yagi, Y; Pressman, D (August 1967). "Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma". Proceedings of the Society for Experimental Biology and Medicine. 125 (4): 1246–50. doi:10.3181/00379727-125-32327. PMID 6042436. S2CID 9643262.
  44. ↑ Nilsson, K; Bennich, H; Johansson, SG; Pontén, J (October 1970). "Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient". Clinical and Experimental Immunology. 7 (4): 477–89. PMC 1712861. PMID 4097745.
  45. 1 2 Drexler, HG; Gaedicke, G; Lok, MS; Diehl, V; Minowada, J (1986). "Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles". Leukemia Research. 10 (5): 487–500. doi:10.1016/0145-2126(86)90084-6. PMID 3713248.
  46. ↑ Kamesaki, H; Fukuhara, S; Tatsumi, E; Uchino, H; Yamabe, H; Miwa, H; Shirakawa, S; Hatanaka, M; Honjo, T (July 1986). "Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease". Blood. 68 (1): 285–92. doi:10.1182/blood.V68.1.285.285. PMID 3013343.
  47. ↑ Wolf, J; Kapp, U; Bohlen, H; Kornacker, M; Schoch, C; Stahl, B; Mücke, S; von Kalle, C; Fonatsch, C; Schaefer, HE; Hansmann, ML; Diehl, V (15 April 1996). "Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells". Blood. 87 (8): 3418–28. doi:10.1182/blood.V87.8.3418.bloodjournal8783418. PMID 8605360.
  48. ↑ Naumovski, L; Utz, PJ; Bergstrom, SK; Morgan, R; Molina, A; Toole, JJ; Glader, BE; McFall, P; Weiss, LM; Warnke, R (December 1989). "SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma". Blood. 74 (8): 2733–42. doi:10.1182/blood.V74.8.2733.2733. PMID 2554995.
  49. ↑ FOLEY, GE; LAZARUS, H; FARBER, S; UZMAN, BG; BOONE, BA; MCCARTHY, RE (April 1965). "Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia". Cancer. 18 (4): 522–9. doi:10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. PMID 14278051. S2CID 32647486.
  50. ↑ Heyman, M; Grandér, D; Bröndum-Nielsen, K; Cederblad, B; Liu, Y; Xu, B; Einhorn, S (March 1994). "Interferon system defects in malignant T-cells". Leukemia. 8 (3): 425–34. PMID 8127147.
  51. ↑ Morikawa, S; Tatsumi, E; Baba, M; Harada, T; Yasuhira, K (15 February 1978). "Two E-rosette-forming lymphoid cell lines". International Journal of Cancer. 21 (2): 166–70. doi:10.1002/ijc.2910210207. PMID 203546. S2CID 9032666.
  52. ↑ Abraham, RT; Weiss, A (April 2004). "Jurkat T cells and development of the T-cell receptor signalling paradigm". Nature Reviews. Immunology. 4 (4): 301–8. doi:10.1038/nri1330. PMID 15057788. S2CID 13253575.
  53. ↑ Minowada, J; Onuma, T; Moore, GE (September 1972). "Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes". Journal of the National Cancer Institute. 49 (3): 891–5. PMID 4567231.
  54. ↑ Huang, CC; Hou, Y; Woods, LK; Moore, GE; Minowada, J (September 1974). "Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia". Journal of the National Cancer Institute. 53 (3): 655–60. doi:10.1093/jnci/53.3.655. PMID 4547172.
  55. ↑ Di Noto, R; Pane, F; Camera, A; Luciano, L; Barone, M; Lo Pardo, C; Boccuni, P; Intrieri, M; Izzo, B; Villa, MR; Macrí, M; Rotoli, B; Sacchetti, L; Salvatore, F; Del Vecchio, L (October 2001). "Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma". Leukemia. 15 (10): 1641–9. doi:10.1038/sj.leu.2402239. PMID 11587224. S2CID 25177712.
  56. ↑ Starkebaum, G; Loughran TP, Jr; Waters, CA; Ruscetti, FW (9 September 1991). "Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor". International Journal of Cancer. 49 (2): 246–53. doi:10.1002/ijc.2910490218. PMID 1879969. S2CID 8605186.
  57. ↑ Matsuo, Y; Drexler, HG; Takeuchi, M; Tanaka, M; Orita, K (September 2002). "Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens". Leukemia Research. 26 (9): 873–9. doi:10.1016/s0145-2126(02)00023-1. PMID 12127564.
  58. ↑ Yagita, M; Huang, CL; Umehara, H; Matsuo, Y; Tabata, R; Miyake, M; Konaka, Y; Takatsuki, K (May 2000). "A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation". Leukemia. 14 (5): 922–30. doi:10.1038/sj.leu.2401769. PMID 10803526. S2CID 22938275.
  59. ↑ Gong, J., Maki, G., and Klingemann, H-G. (1994). “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”. Leukemia; 8: 652-58.
  60. ↑ Yodoi, J; Teshigawara, K; Nikaido, T; Fukui, K; Noma, T; Honjo, T; Takigawa, M; Sasaki, M; Minato, N; Tsudo, M (March 1985). "TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells)". Journal of Immunology. 134 (3): 1623–30. doi:10.4049/jimmunol.134.3.1623. PMID 2578514. S2CID 13147698.
  61. ↑ Barbey, S; Gogusev, J; Mouly, H; Le Pelletier, O; Smith, W; Richard, S; Soulie, J; Nezelof, C (15 March 1990). "DEL cell line: a "malignant histiocytosis" CD30+ t(5;6)(q35;p21) cell line". International Journal of Cancer. 45 (3): 546–53. doi:10.1002/ijc.2910450329. PMID 2307542. S2CID 1472373.
  62. ↑ Su, IJ; Balk, SP; Kadin, ME (August 1988). "Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies". The American Journal of Pathology. 132 (2): 192–8. PMC 1880737. PMID 2456698.
  63. ↑ Epstein, AL; Kaplan, HS (December 1974). "Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas". Cancer. 34 (6): 1851–72. doi:10.1002/1097-0142(197412)34:6<1851::aid-cncr2820340602>3.0.co;2-4. PMID 4140017. S2CID 27701046.
  64. ↑ Morgan, R; Smith, SD; Hecht, BK; Christy, V; Mellentin, JD; Warnke, R; Cleary, ML (June 1989). "Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis". Blood. 73 (8): 2155–64. doi:10.1182/blood.V73.8.2155.2155. PMID 2525056.
  65. ↑ Mayumi, M (June 1992). "EoL-1, a human eosinophilic cell line". Leukemia & Lymphoma. 7 (3): 243–50. doi:10.3109/10428199209053629. PMID 1477652. Archived from the original on 2019-12-23. Retrieved 2019-12-23.
  66. ↑ Gallagher, R; Collins, S; Trujillo, J; McCredie, K; Ahearn, M; Tsai, S; Metzgar, R; Aulakh, G; Ting, R; Ruscetti, F; Gallo, R (September 1979). "Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia". Blood. 54 (3): 713–33. doi:10.1182/blood.V54.3.713.713. PMID 288488.
  67. ↑ Asou, H; Tashiro, S; Hamamoto, K; Otsuji, A; Kita, K; Kamada, N (1 May 1991). "Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation". Blood. 77 (9): 2031–6. doi:10.1182/blood.V77.9.2031.2031. PMID 2018839.
  68. ↑ Mrózek, K; Tanner, SM; Heinonen, K; Bloomfield, CD (November 2003). "Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization". Genes, Chromosomes & Cancer. 38 (3): 249–52. doi:10.1002/gcc.10274. PMID 14506699. S2CID 6018408.
  69. ↑ Lanotte, M; Martin-Thouvenin, V; Najman, S; Balerini, P; Valensi, F; Berger, R (1 March 1991). "NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)". Blood. 77 (5): 1080–6. doi:10.1182/blood.V77.5.1080.1080. PMID 1995093.
  70. ↑ Wang, C; Curtis, JE; Minden, MD; McCulloch, EA (April 1989). "Expression of a retinoic acid receptor gene in myeloid leukemia cells". Leukemia. 3 (4): 264–9. PMID 2538684.
  71. ↑ Matozaki, S; Nakagawa, T; Kawaguchi, R; Aozaki, R; Tsutsumi, M; Murayama, T; Koizumi, T; Nishimura, R; Isobe, T; Chihara, K (April 1995). "Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression". British Journal of Haematology. 89 (4): 805–11. doi:10.1111/j.1365-2141.1995.tb08418.x. PMID 7772516. S2CID 40610063.
  72. ↑ Yanagisawa, K; Horiuchi, T; Fujita, S (15 July 1991). "Establishment and characterization of a new human leukemia cell line derived from M4E0". Blood. 78 (2): 451–7. doi:10.1182/blood.V78.2.451.451. PMID 2070080.
  73. ↑ Matsuo, Y; MacLeod, RA; Uphoff, CC; Drexler, HG; Nishizaki, C; Katayama, Y; Kimura, G; Fujii, N; Omoto, E; Harada, M; Orita, K (September 1997). "Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)". Leukemia. 11 (9): 1469–77. doi:10.1038/sj.leu.2400768. PMID 9305600. S2CID 205678428.
  74. ↑ Ziegler-Heitbrock, HW; Thiel, E; Fütterer, A; Herzog, V; Wirtz, A; Riethmüller, G (15 March 1988). "Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes". International Journal of Cancer. 41 (3): 456–61. doi:10.1002/ijc.2910410324. PMID 3162233. S2CID 23268646.
  75. ↑ Hu, ZB; Ma, W; Zaborski, M; MacLeod, R; Quentmeier, H; Drexler, HG (June 1996). "Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3". Leukemia. 10 (6): 1025–40. PMID 8667638.
  76. ↑ Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K (August 1980). "Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)". International Journal of Cancer. 26 (2): 171–6. doi:10.1002/ijc.2910260208. PMID 6970727. S2CID 43603660.
  77. ↑ Sundström C (May 1976). "Establishment and characterization of a human histiocytic lymphoma cell line (U-937)". Int. J. Cancer. 17 (5): 565–77. doi:10.1002/ijc.2910170504. PMID 178611. S2CID 19334036.
  78. ↑ Chiba, S; Takaku, F; Tange, T; Shibuya, K; Misawa, C; Sasaki, K; Miyagawa, K; Yazaki, Y; Hirai, H (1 November 1991). "Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin". Blood. 78 (9): 2261–8. doi:10.1182/blood.V78.9.2261.2261. PMID 1834251.
  79. ↑ Martin, P; Papayannopoulou, T (1982-06-11). "HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression". Science. 216 (4551): 1233–5. Bibcode:1982Sci...216.1233M. doi:10.1126/science.6177045. PMID 6177045.
  80. ↑ Papayannopoulou, T; Nakamoto, B; Kurachi, S; Tweeddale, M; Messner, H (September 1988). "Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations". Blood. 72 (3): 1029–38. doi:10.1182/blood.V72.3.1029.bloodjournal7231029. PMID 3166384.
  81. ↑ Kitamura, T; Tange, T; Terasawa, T; Chiba, S; Kuwaki, T; Miyagawa, K; Piao, YF; Miyazono, K; Urabe, A; Takaku, F (August 1989). "Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin". Journal of Cellular Physiology. 140 (2): 323–34. doi:10.1002/jcp.1041400219. PMID 2663885. S2CID 44794601.
  82. ↑ Sato, T; Fuse, A; Eguchi, M; Hayashi, Y; Ryo, R; Adachi, M; Kishimoto, Y; Teramura, M; Mizoguchi, H; Shima, Y (June 1989). "Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia". British Journal of Haematology. 72 (2): 184–90. doi:10.1111/j.1365-2141.1989.tb07681.x. PMID 2527057. S2CID 9036646.
  83. 1 2 Miura, Y; Komatsu, N; Suda, T (1990). "Growth and differentiation of two human megakaryoblastic cell lines; CMK and UT-7". Progress in Clinical and Biological Research. 356: 259–70. PMID 2217443.
  84. ↑ Mouthon, MA; Freund, M; Titeux, M; Katz, A; Guichard, J; Breton-Gorius, J; Vainchenker, W (15 August 1994). "Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis". Blood. 84 (4): 1085–97. doi:10.1182/blood.V84.4.1085.1085. PMID 7519473.
  85. ↑ Avanzi, GC; Brizzi, MF; Giannotti, J; Ciarletta, A; Yang, YC; Pegoraro, L; Clark, SC (December 1990). "M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3". Journal of Cellular Physiology. 145 (3): 458–64. doi:10.1002/jcp.1041450310. PMID 2273055. S2CID 39079797.
  86. 1 2 Quentmeier, H; MacLeod, RA; Zaborski, M; Drexler, HG (March 2006). "JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders". Leukemia. 20 (3): 471–6. doi:10.1038/sj.leu.2404081. PMID 16408098. S2CID 1907521.
  87. ↑ Takeuchi, S; Sugito, S; Uemura, Y; Miyagi, T; Kubonishi, I; Taguchi, H; Enzan, H; Ohtsuki, Y; Miyoshi, I (June 1992). "Acute megakaryoblastic leukemia: establishment of a new cell line (MKPL-1) in vitro and in vivo". Leukemia. 6 (6): 588–94. PMID 1602796.
  88. ↑ Raskind, WH; Disteche, CM; Keating, A; Singer, JW (April 1987). "Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3". Cancer Genetics and Cytogenetics. 25 (2): 271–84. doi:10.1016/0165-4608(87)90188-9. PMID 3030532.
  89. ↑ Lozzio CB, Lozzio BB (March 1975). "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome". Blood. 45 (3): 321–334. doi:10.1182/blood.V45.3.321.321. PMID 163658.
  90. ↑ Drexler HG (2000). The Leukemia-Lymphoma Cell Line Factsbook. San Diego: Academic Press.
  91. ↑ Kubonishi, I; Miyoshi, I (June 1983). "Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis". International Journal of Cell Cloning. 1 (2): 105–17. doi:10.1002/stem.5530010205. PMID 6321612.
  92. ↑ Kishi, K (1985). "A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors". Leukemia Research. 9 (3): 381–90. doi:10.1016/0145-2126(85)90060-8. PMID 3858609.
  93. ↑ Seigneurin, D; Champelovier, P; Mouchiroud, G; Berthier, R; Leroux, D; Prenant, M; McGregor, J; Starck, J; Morle, F; Micouin, C (September 1987). "Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics". Experimental Hematology. 15 (8): 822–32. PMID 3476310.
  94. ↑ Pegoraro, L; Matera, L; Ritz, J; Levis, A; Palumbo, A; Biagini, G (March 1983). "Establishment of a Ph1-positive human cell line (BV173)". Journal of the National Cancer Institute. 70 (3): 447–53. PMID 6572735.
  95. ↑ Kuriyama, K; Gale, RP; Tomonaga, M; Ikeda, S; Yao, E; Klisak, I; Whelan, K; Yakir, H; Ichimaru, M; Sparkes, RS (September 1989). "CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia". Blood. 74 (4): 1381–7. doi:10.1182/blood.V74.4.1381.1381. PMID 2788468. S2CID 16883925.
  96. ↑ Minowada, J; Tsubota, T; Greaves, MF; Walters, TR (July 1977). "A non-T, non-B human leukemia cell line (NALM-1): establishment of the cell line and presence of leukemia-associated antigens". Journal of the National Cancer Institute. 59 (1): 83–7. doi:10.1093/jnci/59.1.83. PMID 301573.
  97. ↑ Watanabe, T; Kataoka, T; Mizuta, S; Kobayashi, M; Uchida, T; Imai, K; Wada, H; Kinoshita, T; Murate, T; Mizutani, S (November 1995). "Establishment and characterization of a novel cell line, TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone-related protein". Leukemia. 9 (11): 1926–34. PMID 7475285.
  98. ↑ Uozumi, K; Otsuka, M; Ohno, N; Moriyama, T; Suzuki, S; Shimotakahara, S; Matsumura, I; Hanada, S; Arima, T (January 2000). "Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles". Leukemia. 14 (1): 142–52. doi:10.1038/sj.leu.2401608. PMID 10637490. S2CID 3258153.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.